Patents Assigned to Sanford Burnham Prebys Medical Discovery Institute
-
Patent number: 10988475Abstract: Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).Type: GrantFiled: January 14, 2020Date of Patent: April 27, 2021Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Layton H. Smith
-
Patent number: 10973925Abstract: Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.Type: GrantFiled: April 28, 2016Date of Patent: April 13, 2021Assignees: University of Central Florida Research Foundation Inc., Sanford Burnham Prebys Medical Discovery Institute at Lake Nona, Memorial Sloan Kettering Cancer CenterInventors: Annette Khaled, Jesus Manuel Perez Figueroa, Santimukul Santra, Charalambos Kaittanis, Oscar Santiesteban, Jan Grimm, Hampton Sessions
-
Patent number: 10961297Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.Type: GrantFiled: June 29, 2016Date of Patent: March 30, 2021Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
-
Patent number: 10864217Abstract: Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).Type: GrantFiled: May 24, 2019Date of Patent: December 15, 2020Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Lars Pache, Sumit K. Chanda, Mitchell Dennis Vamos, Nicholas David Peter Cosford, Peter Teriete, John Marlett, Arturo Diaz, John A. T. Young
-
Patent number: 10858436Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.Type: GrantFiled: July 8, 2015Date of Patent: December 8, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Linda M. Bradley, Roberto Tinoco
-
Patent number: 10774092Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.Type: GrantFiled: April 19, 2019Date of Patent: September 15, 2020Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITYInventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
-
Patent number: 10759863Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.Type: GrantFiled: September 4, 2014Date of Patent: September 1, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Carl F. Ware, John R. Sedy
-
Patent number: 10716808Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.Type: GrantFiled: July 7, 2015Date of Patent: July 21, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventor: Alexey V. Terskikh
-
Patent number: 10717765Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: GrantFiled: May 25, 2018Date of Patent: July 21, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Carl Ware, John Sedy
-
Patent number: 10689397Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.Type: GrantFiled: February 6, 2019Date of Patent: June 23, 2020Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, YALE UNIVERSITYInventors: Reuben J. Shaw, Daniel F. Egan, Nicholas Cosford, Benjamin Turk, Mitchell Vamos, Dhanya Raveendra Panickar, Matthew Chun, Douglas Sheffler
-
Patent number: 10682416Abstract: Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.Type: GrantFiled: April 8, 2016Date of Patent: June 16, 2020Assignees: Regencor, Inc., Sanford Burnham Prebys Medical Discovery InstituteInventors: Pilar Ruiz-Lozano, Mark Mercola, Ke Wei
-
Patent number: 10669311Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).Type: GrantFiled: April 22, 2016Date of Patent: June 2, 2020Assignee: Sanford Burnham Prebys Medical Discovery InstituteInventors: Tambet Teesalu, Erkki Ruoslahti, Kazuki Sugahara, Shweta Sharma
-
Patent number: 10653797Abstract: Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain injury, shows selective binding to mouse and human brain injury lesions, and when systemically injected, specifically homes to sites of injury in penetrating and non-penetrating (controlled cortical impact) brain injury models. Also disclosed are methods and compositions for delivering therapeutic compounds to such sites. CAQK-coated nanoparticles containing silencing oligonucleotides provide an alternative to local delivery of therapeutics, which is invasive and can add complications to the injury.Type: GrantFiled: September 2, 2016Date of Patent: May 19, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Erkki Ruoslahti, Aman Mann, Pablo Scodeller, Sazid Hussain
-
Patent number: 10647689Abstract: Provided herein are agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.Type: GrantFiled: April 28, 2016Date of Patent: May 12, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Layton H. Smith, Anthony B. Pinkerton, Paul Hershberger, Patrick Maloney, Danielle McAnally
-
Patent number: 10626094Abstract: Herein are provided, inter alia, compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and methods of using the same. In embodiments, the compound has a structure according to Formula (I-A).Type: GrantFiled: October 14, 2015Date of Patent: April 21, 2020Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGYInventors: Nunzio Bottini, Jiwen Zou, Santhi R. Ganji, Stephanie Stanford, Anthony Pinkerton, Thomas D. Y. Chung, Michael Hedrick, Robert Ardecky
-
Patent number: 10626096Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.Type: GrantFiled: November 21, 2016Date of Patent: April 21, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Takuya Ikeda, Yoshiyuki Kobayashi, Naoki Miyoshi, Osamu Suzuki, Takahiro Nagayama, Takashi Tsuji, Layton H. Smith, Anthony B. Pinkerton
-
Patent number: 10597367Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.Type: GrantFiled: April 11, 2018Date of Patent: March 24, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient
-
Publication number: 20200087321Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: December 22, 2017Publication date: March 19, 2020Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
-
Patent number: 10584103Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.Type: GrantFiled: September 24, 2018Date of Patent: March 10, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
-
Patent number: 10577349Abstract: Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.Type: GrantFiled: March 1, 2016Date of Patent: March 3, 2020Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Ze'ev Ronai, Anthony B. Pinkerton, Yongmei Feng, Ivan Topisirovic, Kevin Brown, Christian A. Hassig